- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04699214
Endostar Combined With AI Regimen Compared With AI in Adjuvant Treatment
A Prospective, Randomized Controlled Phase II Clinical Study Evaluating the Efficacy and Safety of Endostar Combined With AI Regimen Compared With AI Regimen in Adjuvant Treatment After Radical Resection of Recurrent Soft Tissue Sarcoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Eligible patients with stage IIB/III soft tissue sarcoma after surgical treatment for local recurrence were randomly divided into three groups:
Group A: Endostar combined chemotherapy AI Endostar: Endostar 45mg/d, D1-5 iv, Q3W, that is, continuous intravenous pump injection for 120 hours for 5 consecutive days, one cycle. Endostar takes 15 medicines per cycle, and a Baxter pump per single cycle. Subjects buy and use them at their own expense every two cycles.
AI: Doxorubicin (ADM) 60mg/m2 iv D1+ Ifosfamide (IFO) 2g/m2/d D1-5+ Mesna 400mg/m 2 (ifosfamide start infusion, time after infusion 4 hours, 8 hours injection) D1-5, Q3W.
Group B:Chemotherapy AI AI: Doxorubicin (ADM) 60mg/m2 iv D1+ Ifosfamide (IFO) 2g/m2/d D1-5+ Mesna 400mg/m 2 (ifosfamide start infusion, time after infusion 4 hours, 8 hours injection) D1-5, Q3W.
Group C: Observation group Best supportive treatment, observation and follow-up. The dose of Endostar is not adjusted, and the specific adjustment plan of the chemotherapy regimen is adjusted according to the clinical experience of the investigator.
Patients with no disease progression (local tumor recurrence, distant metastasis, or the appearance of new lesions of the same tumor subtype) and the adverse reactions can be tolerated, continue to use the drug for 6 cycles, and cannot receive other anti-tumor treatments. During the medication, if the disease progresses or the researcher believes that the patient is not suitable for continuing medication, the medication will end.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200000
- Recruiting
- Fudan University Shanghai Cancer Center
-
Contact:
- Chen Yong, Doctor
- Phone Number: 13917530417
- Email: chenyong@fudan.edu.cn
-
Contact:
- Dong Yan, master
- Phone Number: 15259205312
- Email: dongyan20202020@126.com
-
Principal Investigator:
- Chen Yong, Doctor
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with soft tissue sarcoma confirmed by histopathology and cytology;
- Patients with soft tissue sarcoma judged to be stage IIB/III according to the AJCC staging of soft tissue sarcoma;
- Patients who have previously undergone surgery can be included in the group, but according to the researcher's evaluation, they must have recovered and the operation completion time is at least 4 weeks from the study entry;
- Local radiotherapy can be received during chemotherapy;
- Have received anti-tumor drug treatment in the past, including adjuvant or neoadjuvant chemotherapy, but it has been over 6 months before the start of the study treatment;
- R0 resection after local recurrence, non-chemotherapeutic resistant soft tissue sarcoma, including synovial sarcoma, pleomorphic liposarcoma, myxoid/round cell liposarcoma, pleomorphic undifferentiated sarcoma, leiomyosarcoma, myxofibrosarcoma, Angiosarcoma, malignant peripheral nerve sheath tumor, epithelioid sarcoma, etc., except Ewing's sarcoma, embryonic/acinoid rhabdomyosarcoma and other sarcomas that do not use AI regimen as the first-line chemotherapy regimen, and some chemotherapy-insensitive sarcomas: highly differentiated/removed Differentiated liposarcoma, clear cell sarcoma, alveolar soft tissue sarcoma, extraosseous mucinous chondrosarcoma, etc.;
- No gender limit, ≥18 years old;
- ECOG score ≤ 2;
- The expected survival period is ≥3 months;
- Sufficient blood function: absolute neutrophil count (ANC)≥1.5×109/L and platelet count≥80×109/L and hemoglobin≥9 g/dL;
- Sufficient liver function: total bilirubin ≤ upper limit of normal (ULN); AST and ALT ≤ 1.5 times upper limit of normal (ULN); alkaline phosphatase ≤ 5 times upper limit of normal (ULN);
- Sufficient renal function: serum creatinine ≤ upper limit of normal (ULN) or calculated creatinine clearance ≥ 60 mL/min;
- The electrocardiogram is basically normal, and there is no unhealed wound on the body;
- Those who have not had a severe allergic reaction to biological agents, especially E. coli genetic engineering products;
- Women of childbearing age must agree to use contraceptive measures (such as intrauterine device (IUD), contraceptives or condoms) during the study period and within 6 months after the end of the study; serum or urine pregnancy within 7 days before study entry The test is negative and must be a non-lactating patient; men should agree to use contraception during the study period and within 6 months after the end of the study period.
- The patient voluntarily joined the study, signed an informed consent form, had good compliance, and was able to be followed up by the trial staff.
Exclusion Criteria:
- Pregnant or lactating women, or female patients who are fertile but have not taken contraceptive measures;
- There are severe acute infections that have not been controlled; or there are purulent and chronic infections, and the wounds do not heal;
- There is a second primary tumor (except skin basal cell carcinoma);
- Those who have participated in other drug clinical trials within 4 weeks.
- Pre-existing severe heart disease, including: congestive heart failure, uncontrollable high-risk arrhythmia, unstable angina, myocardial infarction, severe heart valve disease, and refractory hypertension;
- People with uncontrollable neurological or mental illnesses or mental disorders, poor compliance, and unable to cooperate and describe the treatment response; primary brain tumors or central nerve metastases have not been controlled, and have obvious intracranial hypertension or neuropsychiatry Symptoms;
- Those with bleeding tendency;
- Evidence of hereditary hemorrhagic constitution or coagulopathy;
- A clear history of allergy to chemotherapy drugs
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Endostar combined with chemotherapy AI
Endostar: Endostar 45mg/d, D1-5 iv, Q3W, that is, continuous intravenous pump injection for 120 hours for 5 consecutive days, one cycle. Endostar uses 15 medicines per cycle, 15 Endostar medicines and a Baxter pump per single cycle. Subjects buy and use them at their own expense every two cycles. AI: Doxorubicin (ADM) 60mg/m2 iv D1+ Ifosfamide (IFO) 2g/m2/d D1-5+ Mesna 400mg/m 2 (ifosfamide start infusion, time after infusion 4 hours, 8 hours injection) D1-5, Q3W. |
The experimental group is Endostar combined with AI
|
Active Comparator: Chemotherapy AI
AI: Doxorubicin (ADM) 60mg/m2 iv D1+ Ifosfamide (IFO) 2g/m2/d D1-5+ Mesna 400mg/m 2 (ifosfamide start infusion, time after infusion 4 hours, 8 hours injection) D1-5, Q3W.
|
AI: Doxorubicin (ADM) 60mg/m2 iv D1+ Ifosfamide (IFO) 2g/m2/d D1-5+ Mesna 400mg/m 2 (ifosfamide start infusion, time after infusion 4 hours, 8 hours injection) D1-5, Q3W
|
Placebo Comparator: Observation group
The dose of Endostar is not adjusted, and the specific adjustment plan of the chemotherapy regimen is adjusted according to the clinical experience of the investigator. Patients with no disease progression (local tumor recurrence, distant metastasis, or the appearance of new lesions of the same tumor subtype) and the adverse reactions can be tolerated, continue to use the drug for 6 cycles, and cannot receive other anti-tumor treatments. In the course of medication, if the disease progresses or the researcher believes that the patient is not suitable for continuing medication, the medication will end. |
The experimental group is Endostar combined with AI
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
EFS (Event-Free Survival Rate)
Time Frame: 2 year
|
Prospective observation of the 2-year event-free survival rate EFS (Event-Free Survival Rate) of recombinant human endostatin injection (Endostar, trade name: Endostar) combined with adjuvant chemotherapy for local recurrence of soft tissue sarcoma, ie no progress , No disease-related deaths, no time for new lesions.
|
2 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
OS(Overall Survival)
Time Frame: 2 year
|
To evaluate the OS (Overall Survival)
|
2 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1906203-3
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Other Disorders of Soft Tissues
-
Istituto Clinico HumanitasActive, not recruitingMetastasis From Malignant Tumor of Soft TissuesItaly
-
University of ValenciaActive, not recruitingOutcome | Prosthetic | Soft Tissues
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingLocalized Extraskeletal Ewing Sarcoma | Peripheral Primitive Neuroectodermal Tumor of Bone | Peripheral Primitive Neuroectodermal Tumor of Soft TissuesUnited States, Canada, Saudi Arabia, Australia, New Zealand, Puerto Rico
-
Philips HealthcarePhilips Electronics Nederland B.V. acting through Philips CTO organizationCompletedMalignant Lymphoma of Lymph Nodes of Inguinal Region | Malignant Lymphoma of Lymph Nodes of Axillary | Malignant Lymphoma of Lymph Nodes of the Cervix | Carcinoma of Parotid Gland | Colon Rectal Cancer Tubulovillous Adenocarcinoma | Tumor of Soft Tissue of Head, Face and NeckNetherlands
-
University of ArkansasWithdrawnThin Sections | Fresh Unfixed Tissues | Fresh Unfrozen Tissues
-
Cairo UniversityActive, not recruitingTooth Discoloration | Dental Disorders Hard Tissues of TeethEgypt
-
Ivoclar Vivadent AGUniversity of MichiganRecruitingDental Diseases | Dental Disorders Hard Tissues of TeethUnited States
-
PfizerCompletedIntra-Abdominal Infections | Skin Disease, Infectious | Soft Tissues Infections
-
University of British ColumbiaCompletedOther Disorders of Optic Disc, BilateralCanada
-
Sohag UniversityRecruitingReconstruction of Head Soft Tissue Defects | Reconstruction of Neck Soft Tissue DefectsEgypt
Clinical Trials on Endostar (recombinant human endostatin injection)
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingGastrointestinal NeoplasmsChina
-
Zhejiang Cancer HospitalUnknown
-
Zhejiang UniversityBeta Pharma, Inc.; Jiangsu Simcere Pharmaceutical Co., Ltd.Unknown
-
Tianjin Medical University Cancer Institute and...CompletedSoft Tissue Sarcoma, Adult, Stage IIBChina
-
China International Medical FoundationChinese Society of Clinical OncologyUnknown
-
Anhui Chest HospitalNot yet recruitingCarcinoma, Non-Small-Cell Lung
-
First Affiliated Hospital of Guangxi Medical UniversityUnknownNasopharyngeal CarcinomaChina
-
Simcere Pharmaceutical Co., LtdThe Affiliated Changzhou Tumor Hospital of Suzhou UniversityUnknownColorectal NeoplasmsChina
-
Zhejiang Cancer HospitalUnknownCervical CancerChina
-
Jiangsu Simcere Pharmaceutical Co., Ltd.Not yet recruitingAdvanced or Metastatic NSCLCChina